Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 1 085.19 USD -2.07% Market Closed
Market Cap: 1T USD

Relative Value

The Relative Value of one LLY stock under the Base Case scenario is 363.4 USD. Compared to the current market price of 1 085.19 USD, Eli Lilly and Co is Overvalued by 67%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LLY Relative Value
Base Case
363.4 USD
Overvaluation 67%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
9
Median 3Y
16.2
Median 5Y
13.6
Industry
2.6
Forward
16.2
vs History
42
vs Industry
5
Median 3Y
69.1
Median 5Y
54.5
Industry
21.4
Forward
45.9
vs History
41
vs Industry
5
Median 3Y
81.4
Median 5Y
55.8
Industry
16.4
vs History
50
vs Industry
5
Median 3Y
84.2
Median 5Y
62.8
Industry
22.8
vs History
34
vs Industry
0
Median 3Y
46.5
Median 5Y
36.6
Industry
2.2
vs History
20
vs Industry
8
Median 3Y
16.8
Median 5Y
14.1
Industry
2.9
Forward
16.7
vs History
22
vs Industry
9
Median 3Y
20.9
Median 5Y
17.1
Industry
5.5
vs History
38
vs Industry
7
Median 3Y
47.2
Median 5Y
34
Industry
13
Forward
37.4
vs History
41
vs Industry
8
Median 3Y
54.1
Median 5Y
39.7
Industry
16.5
Forward
40.1
vs History
41
vs Industry
5
Median 3Y
84.1
Median 5Y
58
Industry
15.6
vs History
6
vs Industry
0
Median 3Y
-190.3
Median 5Y
48.5
Industry
18.7
vs History
22
vs Industry
8
Median 3Y
10.1
Median 5Y
8.2
Industry
1.9

Multiples Across Competitors

LLY Competitors Multiples
Eli Lilly and Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.5B USD 5.4 19.8 16.2 21.1
CH
Roche Holding AG
SIX:ROG
268.8B CHF 4.4 28.5 12.1 14.2
UK
AstraZeneca PLC
LSE:AZN
219.6B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
277.5B USD 4.3 14.6 10.3 12.2
CH
Novartis AG
SIX:NOVN
219.4B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 14.7 7.5 10.2
FR
Sanofi SA
PAR:SAN
100.9B EUR 1.5 7.3 6.7 6.7
P/E Multiple
Earnings Growth PEG
US
Eli Lilly and Co
NYSE:LLY
Average P/E: 23.1
56.7
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 400.7
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.7
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBIT: 1 713.1
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5
FR
Sanofi SA
PAR:SAN
6.7
15%
0.4